Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …

Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The authors define molecular imaging, according to the Society of Nuclear Medicine and
Molecular Imaging, as the visualization, characterization, and measurement of biological …

Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …